The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock

Virulence

Volumn 5, Issue 1, 2014, Pages 206-212

  Pop Vicas, Aurora ^a   Opal, Steven M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Bacterial resistance; Extended antibiotic resistance; Multidrug resistance; Sepsis; Septic shock

Indexed keywords

AVIBACTAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; BIAPENEM; CARBAPENEM; CEFOTAXIME; CEFTAROLINE; CEFTAZIDIME; CEFTOLOZANE; CEPHALOSPORIN; COLISTIN; DORIPENEM; ERAVACYCLINE; FOSFOMYCIN; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN; PLAZOMICIN; POLYMYXIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; BACTEREMIA; CYSTIC FIBROSIS; ESCHERICHIA COLI INFECTION; GENE MUTATION; HEALTH CARE; HUMAN; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE INFECTION; LUNG INFECTION; MICROBIAL COLONIZATION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PREVALENCE; PSEUDOMONAS INFECTION; REVIEW; SEPTIC SHOCK; ANTIBIOTIC RESISTANCE; DRUG EFFECT; EXTENDED ANTIBIOTIC RESISTANCE; GENETICS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; MICROBIOLOGY; MORTALITY; PHYSIOLOGY; SEPSIS;

BACTERIAL RESISTANCE; EXTENDED ANTIBIOTIC RESISTANCE; MULTIDRUG RESISTANCE; SEPSIS; SEPTIC SHOCK;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; SHOCK, SEPTIC;

EID: 84891657775     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.26210     Document Type: Review

References (65)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12. PMID:19035777; http://dx.doi.org/10.1086/595011
2. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. N Engl J Med 2009; 360:439-443. PMID:19179312; http://dx.doi.org/10.1056/NEJMp0804651
3. Rossi F, Baquero F, Hsueh PR, Paterson DL, Bochicchio GV, Snyder TA, Satishchandran V, McCarroll K, DiNubile MJ, Chow JW. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006; 58:205-210. PMID:16717055; http://dx.doi.org/10.1093/jac/dkl199
4. Cornaglia G, Giamarellou H, Rossolini GM.metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis 2011; 11:381-393. PMID:21530894; http://dx.doi.org/10.1016/S1473-3099(11)70056-1
5. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53:60-7. PMID:21653305; http://dx.doi.org/10.1093/cid/cir202
6. Centers for Disease Control and Prevention (CDC). Vital signs: carbapenem-resistant Enterobacteriaceae.mMWR Morb Mortal Wkly Rep 2013; 62:165-170. PMID:23466435
7. Tängdén T, Cars O, Melhus A, Löwdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extendedspectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010; 54:3564-8. PMID:20547788; http://dx.doi.org/10.1128/AAC.00220-10
8. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11:355-362. PMID:21478057; http://dx.doi.org/10.1016/S1473-3099(11)70059-7
9. Anon.municipal Council of Delhi: 18% DJB water not potable. Reported in Times of India 11 March 2011. http://artciles.timesofindia.indiatimes/com/2011-03-11/delhi/28679651_1_djb-water-drinking-water-samples
10. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 2006; 6:130. PMID:16914034; http://dx.doi.org/10.1186/1471-2334-6-130
11. Morgan DJ, Liang SY, Smith CL, Johnson JK, Harris AD, Furuno JP, Thom KA, Snyder GM, Day HR, Perencevich EN. Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns, and hands of healthcare workers. Infect Control Hosp Epidemiol 2010; 31:716-721. PMID:20486855; http://dx.doi.org/10.1086/653201
12. Doi Y, Adams J, O'Keefe A, Quereshi Z, Ewan L, Paterson DL. Community-acquired extended-spectrum beta-lactamase producers, United States. Emerg Infect Dis 2007; 13:1121-3. PMID:18214201; http://dx.doi.org/10.3201/eid1307.070094
13. Freeman JT, McBride SJ, Heffernan H, Bathgate T, Pope C, Ellis-Pegler RB. Community-onset genitourinary tract infection due to CTX-M-15-Producing Escherichia coli among travelers to the Indian subcontinent in New Zealand. Clin Infect Dis 2008; 47:689-692. PMID:18665816; http://dx.doi.org/10.1086/590941
14. Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, Johnson AP, Pike R, Warner M, Cheasty T, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004; 54:735-743. PMID:15347638; http://dx.doi.org/10.1093/jac/dkh424
15. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352:380-391. PMID:15673804; http://dx.doi.org/10.1056/NEJMra041359
16. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009; 12:476-481. PMID:19716760; http://dx.doi.org/10.1016/j.mib.2009.08.001
17. Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 2012; 39:283-294. PMID:22386741; http://dx.doi.org/10.1016/j.ijantimicag.2011.12.012
18. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51:286-294. PMID:20572763; http://dx.doi.org/10.1086/653932
19. Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, Riddell K, Rogers P, Qin X, Butler-Wu S, et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 2013; 207:919-928. PMID:23288927; http://dx.doi.org/10.1093/infdis/jis933
20. Jacoby GA. AmpC beta-lactamases. [Table of Contents.]. Clin Microbiol Rev 2009; 22:161-182. PMID:19136439; http://dx.doi.org/10.1128/cMR.00036-08
21. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-590. PMID:1892329; http://dx.doi.org/10.7326/0003-4819-115-8-585
22. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 2006; 50:3098-3101. PMID:16940107; http://dx.doi.org/10.1128/AAC.00438-06
23. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP; Colombian Nosocomial Resistance Study Group. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother 2007; 51:1553-5. PMID:17261621; http://dx.doi.org/10.1128/AAC.01405-06
24. Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 2003; 47:1297-1300. PMID:12654661; http://dx.doi.org/10.1128/AAC.47.4.1297-1300.2003
25. Logan LK. Carbapenem-resistant enterobacteriaceae: an emerging problem in children. Clin Infect Dis 2012; 55:852-9. PMID:22700827; http://dx.doi.org/10.1093/cid/cis543
26. Bonomo RA, Szabo D.mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43(Suppl 2):S49-S56. PMID:16894515; http://dx.doi.org/10.1086/504477
27. Piddock LJ.mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 1999; 58(Suppl 2):11-8. PMID:10553699; http://dx.doi.org/10.2165/00003495-199958002-00003
28. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 2007; 45:88-94. PMID:17554708; http://dx.doi.org/10.1086/518605
29. Zhou Y, Yu H, Guo Q, Xu X, Ye X, Wu S, Guo Y, Wang M. Distribution of 16S rRNA methylases among different species of Gram-negative bacilli with high-level resistance to aminoglycosides. Eur J Clin Microbiol Infect Dis 2010; 29:1349-1353. PMID:20614151; http://dx.doi.org/10.1007/s10096-010-1004-1
30. Westbrock-Wadman S, Sherman DR, Hickey MJ, Coulter SN, Zhu YQ, Warrener P, Nguyen LY, Shawar RM, Folger KR, Stover CK. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 1999; 43:2975-2983. PMID:10582892
31. Garcin F, Leone M, Antonini F, Charvet A, Albanèse J, Martin C. Non-adherence to guidelines: an avoidable cause of failure of empirical antimicrobial therapy in the presence of difficult-to-treat bacteria. Intensive Care Med 2010; 36:75-82. PMID:19777208; http://dx.doi.org/10.1007/s00134-009-1660-8
32. Zavascki AP, Barth AL, Gonçalves AL, Moro AL, Fernandes JF, Martins AF, Ramos F, Goldani LZ. The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother 2006; 58:387-392. PMID:16751638; http://dx.doi.org/10.1093/jac/dkl239
33. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, Rossolini GM, Souli M, Giamarellou H. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 2010; 16:102-111. PMID:20085604; http://dx.doi.org/10.1111/j.1469-0691.2009.03115.x
34. Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol 2008; 19:413-418. PMID:19436571
35. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008; 134:281-7. PMID:18682456; http://dx.doi.org/10.1378/chest.08-1116
36. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51:1987-1994. PMID:17387156; http://dx.doi.org/10.1128/AAC.01509-06
37. Rice LB. The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. Clin Infect Dis 2008; 46:491-6. PMID:18194098; http://dx.doi.org/10.1086/526535
38. Wiener-Well Y, Rudensky B, Yinnon AM, Kopuit P, Schlesinger Y, Broide E, Lachish T, Raveh D. Carriage rate of carbapenem-resistant Klebsiella pneumoniae in hospitalised patients during a national outbreak. J Hosp Infect 2010; 74:344-9. PMID:19783067; http://dx.doi.org/10.1016/j.jhin.2009.07.022
39. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327. PMID:18158437; http://dx.doi.org/10.1097/01.CCM.0000298158.12101.41
40. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596. PMID:16625125; http://dx.doi.org/10.1097/01.CCM.0000217961.75225.E9
41. Leekha S, Standiford HC. Empiric antimicrobial therapy for Gram-negative sepsis: back to the future. Crit Care Med 2011; 39:1995-6. PMID:21768802; http://dx.doi.org/10.1097/CCM.0b013e318223b94b
42. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, et al.; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38:1773-1785. PMID:20639750; http://dx.doi.org/10.1097/cCM.0b013e3181eb3ccd
43. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010; 362:1804-1813. PMID:20463340; http://dx.doi.org/10.1056/NEJMra0904124
44. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010; 38:1651-1664. PMID:20562695; http://dx.doi.org/10.1097/CCM.0b013e3181e96b91
45. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31-7. PMID:15206050; http://dx.doi.org/10.1086/420816
46. Thomson KS, Moland ES. Cefepime, piperacillintazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45:3548-3554. PMID:11709338; http://dx.doi.org/10.1128/AAC.45.12.3548-3554.2001
47. Horton J, Pankey GA. Polymyxin B, colistin, and sodium colistimethate.med Clin North Am 1982; 66:135-142. PMID:6278236
48. Hanberger H, Giske CG, Giamarellou H. When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock. Curr Infect Dis Rep 2011; 13:416-425. PMID:21800232; http://dx.doi.org/10.1007/s11908-011-0200-1
49. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943-950. PMID:22752516; http://dx.doi.org/10.1093/cid/cis588
50. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. Treatment outcome of bacteremia due to KPCproducing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56:2108-2113. PMID:22252816; http://dx.doi.org/10.1128/AAC.06268-11
51. Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2012; 56:3395-8. PMID:22430958; http://dx.doi.org/10.1128/AAC.06364-11
52. Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, Belabbes H, Benbachir M. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53:274-278. PMID:16442632; http://dx.doi.org/10.1016/j.jinf.2005.11.019
53. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-1011. PMID:10452626; http://dx.doi.org/10.1086/514732
54. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35:194-199. PMID:20006471; http://dx.doi.org/10.1016/j.ijantimicag.2009.10.005
55. Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43(Suppl 2):S95-S99. PMID:16894522; http://dx.doi.org/10.1086/504486
56. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, Mussap M, Artioli S, Ansaldi F, Durando P, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61:417-420. PMID:18174197; http://dx.doi.org/10.1093/jac/dkm509
57. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48:1724-8. PMID:19438394; http://dx.doi.org/10.1086/599225
58. Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, Nicolaou C, Yphantis D, Antoniadou A, Trikka-Graphakos E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009; 58:273-284. PMID:19344841; http://dx.doi.org/10.1016/j.jinf.2009.02.009
59. Curcio D. Tigecycline for treating bloodstream infections: a critical analysis of the available evidence. Diagn Microbiol Infect Dis 2008; 61:358-9, author reply 360-1. PMID:18342476; http://dx.doi.org/10.1016/j. diagmicrobio.2008.01.025
60. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46:567-570. PMID:18199038; http://dx.doi.org/10.1086/526775
61. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum betalactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10:43-50. PMID:20129148; http://dx.doi.org/10.1016/S1473-3099(09)70325-1
62. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37:415-9. PMID:21429716; http://dx.doi.org/10.1016/j.ijantimicag.2011.01.012
63. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16:184-6. PMID:19694767; http://dx.doi.org/10.1111/j.1469-0691.2009.02921.x
64. Boucher HW, Talbot GH, Benjamin DK Jr., Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D; Infectious Diseases Society of America. 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:1685-1694. PMID:23599308; http://dx.doi.org/10.1093/cid/cit152
65. Diazgranados CA, Cardo DM, McGowan JE Jr. Antimicrobial resistance: international control strategies, with a focus on limited-resource settings. Int J Antimicrob Agents 2008; 32:1-9. PMID:18550343; http://dx.doi.org/10.1016/j.ijantimicag.2008.03.002